Amneal promotes Jason Daly to EVP, Chief Legal Officer; base salary $575k

Amneal Pharmaceuticals, Inc.

Promoted from SVP to EVP, Chief Legal Officer & Corporate Secretary, effective March 1, 2025.
Employment agreement includes initial term through March 31, 2027, with auto-renewal.
Annual base salary of $575,000; bonus target 55% of base with performance multiplier 0-150%.
Severance: 150% of salary, prorated bonus, 18-month benefits, and 12-month outplacement.
Change-in-control protection: equity vesting acceleration and extended exercisability.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jason Daly

Executive Vice President, Chief Legal Officer & Corporate Secretary

AMRX · Amneal Pharmaceuticals, Inc.

Effective: 2025-03-01
Filed: March 6, 2025, 6:59 PM ET

The Agreement provides that, as of the Effective Date, Mr. Daly will be employed as the Company’s Executive Vice President, Chief Legal Officer & Corporate Secretary at an annual base salary of $575,000.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason Daly changed role as Executive Vice President, Chief Legal Officer & Corporate Secretary at Amneal Pharmaceuticals, Inc..

Action: promoted
Role: Executive Vice President, Chief Legal Officer & Corporate Secretary

Exact text from the filing

The Agreement provides that, as of the Effective Date, Mr. Daly will be employed as the Company’s Executive Vice President, Chief Legal Officer & Corporate Secretary at an annual base salary of $575,000.

View on SEC.gov

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001723128-25-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.